BEAM
Beam Therapeutics Inc.Company Information
- Company Name
- Beam Therapeutics Inc.
- CIK
- CIK0001745999
- Category
- Large accelerated filer
- Ticker: Exchange
- BEAM: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- BEAM
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-07-27
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 547,767
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 106,419,208
- Shares outstanding
- 104,326,669
- Ownership
- 102.01%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- 3.42%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 220 | 288 | 295 | 268 | 282 | 528 | 282 | 230 | 293 | 288 | 436 | 169 | ||||||
| Marketable Securities Current | 933 | 923 | 950 | 807 | 868 | 692 | 569 | 696 | 715 | 807 | - | 846 | ||||||
| Prepaid Expense And Other Assets Current | 26 | 55 | 23 | 24 | 25 | 28 | 27 | 20 | 21 | 27 | 21 | 24 | ||||||
| Assets Current | 1,179 | 1,267 | 1,269 | 1,099 | 1,175 | 1,248 | 878 | 946 | 1,029 | 1,122 | 1,211 | 1,040 | ||||||
| Property Plant And Equipment Net | 98 | 101 | 105 | 108 | 109 | 110 | 111 | 114 | 117 | 121 | 125 | 128 | ||||||
| Restricted Cash Noncurrent | 7 | 7 | 7 | 7 | 7 | 7 | 8 | 7 | 6 | 6 | 9 | 9 | ||||||
| Operating Lease Right Of Use Asset | 96 | 98 | 101 | 97 | 100 | 102 | 105 | 105 | 107 | 109 | 113 | 112 | ||||||
| Other Assets Noncurrent | 8 | 8 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | ||||||
| Assets | 1,386 | 1,481 | 1,481 | 1,311 | 1,391 | 1,467 | 1,104 | 1,171 | 1,261 | 1,360 | 1,460 | 1,291 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 13 | 12 | 10 | 10 | 11 | 8 | 4 | 4 | 4 | 3 | 2 | 3 | ||||||
| Accrued Liabilities And Other Liabilities | 40 | 39 | 55 | 42 | 41 | 30 | 47 | 52 | 67 | 86 | - | 42 | ||||||
| Derivative Liabilities Current | 9 | 5 | 8 | 7 | 4 | 5 | 8 | 8 | 8 | 14 | 11 | 9 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 7 | 110 | 106 | 85 | 109 | 89 | 85 | 72 | 69 | 153 | ||||||
| Operating Lease Liability Current | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 12 | 13 | 12 | ||||||
| Finance Lease Liability Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Business Combination Contingent Consideration Liability Current | 3 | 3 | 3 | 1 | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 81 | 75 | 97 | 183 | 174 | 142 | 182 | 166 | 177 | 187 | 206 | 220 | ||||||
| Operating Lease Liability Noncurrent | 132 | 136 | 140 | 139 | 142 | 145 | 148 | 149 | 153 | 156 | 160 | 161 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 6 | 5 | 6 | 7 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 5 | ||||||
| Contract With Customer Liability Noncurrent | - | - | 0 | 10 | 20 | 49 | 33 | 58 | 75 | 100 | 110 | 125 | ||||||
| Derivative Liabilities Noncurrent | - | - | 0 | 7 | 6 | 6 | 5 | 5 | - | - | - | - | ||||||
| Long Term Debt Noncurrent | 100 | 100 | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | ||||||
| Liabilities | 319 | 316 | 243 | 345 | 344 | 344 | 370 | 380 | 407 | 446 | 478 | 512 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital | 2,927 | 2,900 | 2,877 | 2,855 | 2,824 | 2,798 | 2,299 | 2,265 | 2,234 | 2,202 | 2,170 | 2,113 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | -1 | 1 | 1 | 0 | 0 | 1 | 2 | -1 | -1 | 1 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -1,858 | -1,736 | -1,641 | -1,891 | -1,778 | -1,676 | -1,567 | -1,476 | -1,380 | -1,289 | -1,190 | -1,333 | ||||||
| Stockholders Equity | 1,067 | 1,164 | 1,238 | 966 | 1,053 | 1,129 | 734 | 791 | 854 | 913 | 981 | 779 | ||||||
| Liabilities And Stockholders Equity | 1,386 | 1,481 | 1,481 | 1,311 | 1,391 | 1,467 | 1,104 | 1,171 | 1,261 | 1,360 | 1,460 | 1,291 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 103 | 103 | 102 | 101 | 101 | 101 | 84 | 83 | 82 | 82 | 82 | 79 | ||||||
| Shares Outstanding | 103 | 103 | 102 | 101 | 101 | 101 | 84 | 83 | 82 | 82 | 82 | 79 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBeam Therapeutics Inc. (BEAM) — SEC Financial Statements & Analysis
Beam Therapeutics Inc. (BEAM) is a biological products, (no diagnostic substances) company, incorporated in DE. Beam Therapeutics Inc. trades on Nasdaq as: BEAM. Beam Therapeutics Inc. (BEAM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Beam Therapeutics Inc. carries a market cap of $3.58B, a P/E ratio of -41.38x, a P/B ratio of 3.35x, a P/S ratio of 22.95x, an enterprise value of $3.45B, and an EV/EBITDA multiple of -9.71x. On profitability, it posts an operating margin of -242.27%, a net margin of -55.45%, a Return on Equity (ROE) of -8.16%, a Return on Assets (ROA) of -6.23%, and a Return on Invested Capital (ROIC) of -44.21%. Per share, it reports EPS of $-0.83, diluted EPS of $-0.83, free cash flow per share of $-3.57, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 158.88% year-over-year, net income growth of -78.23% year-over-year, and EPS growth of -78.72% year-over-year. On the balance sheet, it maintains a current ratio of 14.57x, a quick ratio of 14.25x, working capital of $1.10B, a debt-to-equity ratio of 0.30x, a debt ratio of 0.23, free cash flow of $-372.77M (TTM), and net debt of $-126.28M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.58B
- P/E TTM
- -41.38x
- EPS TTM
- $-0.83
- P/B TTM
- 3.35x
- ROE TTM
- -8.16%
- ROA TTM
- -6.23%
- Debt To Equity
- 0.30x
- Free Cash Flow TTM
- $-372.77M
- Net Revenue TTM Growth 1Y
- 158.88%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. (BEAM) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does BEAM trade on?
Beam Therapeutics Inc. (BEAM) trades on the Nasdaq.
Where is Beam Therapeutics Inc. incorporated?
Beam Therapeutics Inc. is incorporated in DE.
When was Beam Therapeutics Inc. (BEAM)'s most recent SEC filing?
Beam Therapeutics Inc. (BEAM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is BEAM's market cap?
Beam Therapeutics Inc. (BEAM) has a market capitalization of $3.58B as of 2026-06-30.
What is BEAM's EPS (earnings per share)?
Beam Therapeutics Inc. (BEAM)'s trailing twelve month EPS is $-0.83 as of 2026-06-30.
What is BEAM's ROE (return on equity)?
Beam Therapeutics Inc. (BEAM)'s trailing twelve month Return on Equity (ROE) is -8.16% as of 2026-06-30.
What is BEAM's ROA (return on assets)?
Beam Therapeutics Inc. (BEAM)'s trailing twelve month Return on Assets (ROA) is -6.23% as of 2026-06-30.
What is BEAM's ROIC (return on invested capital)?
Beam Therapeutics Inc. (BEAM)'s trailing twelve month Return on Invested Capital (ROIC) is -44.21% as of 2026-06-30.
What is BEAM's EV/EBITDA?
Beam Therapeutics Inc. (BEAM)'s trailing twelve month EV/EBITDA is -9.71x as of 2026-06-30.